NovoCure Limited - Ordinary Shares (NVCR): Downgrade News

NVCR – Wells Fargo cuts to market perform. Stock price at the time of this analyst call was $8.15.


Update: As of Mar. 28, 2017, this bearish analyst call has returned -1.53%.


Key Facts Surrounding This News Item


  • NVCR had a POWR Rating of D (Sell) coming into today.
  • NVCR was 2.32% above its 10-Day Moving Average coming into today.
  • NVCR was -1.95% below its 20-Day Moving Average coming into today.
  • NVCR was -0.89% below its 50-Day Moving Average coming into today.
  • NVCR was 0.34% above its 100-Day Moving Average coming into today.
  • NVCR was -17.70% below its 200-Day Moving Average coming into today.
  • NVCR had returned +3.82% year-to-date leading up to today’s news, versus a +1.31% return from the benchmark S&P 500 during the same period.

More Info About NovoCure Limited – Ordinary Shares (NVCR)


NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands. View our full NVCR ticker page with ratings, news, and more.

NVCR at a Glance

NVCR Current POWR Rating™
Overall POWR Rating™
NVCR Current Price $8.03 5.59%
More NVCR Ratings, Data, and News

NVCR Price Reaction

The day of this event (Jan. 11, 2017)
NVCR Closing Price$7.40 9.20%
NVCR Volume548,000
41.75% from avg
Leading up to this event
NVCR 1-mo returnN/A%
After this event
NVCR 1-day return14.79%
NVCR 3-day return23.48%
NVCR 5-day return21.64%

NVCR Price Chart

More NovoCure Limited - Ordinary Shares (NVCR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NVCR News
Page generated in 1.0454 seconds.